A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe

BACKGROUND: DCZ3301, a novel aryl-guanidino compound previously reported by our group, exerts cytotoxic effects against multiple myeloma (MM), diffused large B cell lymphoma (DLBCL), and T-cell leukemia/lymphoma. However, the underlying mechanism of its action remains unknown. METHODS: We generated...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Liangning, Li, Bo, Chen, Gege, Song, Dongliang, Xu, Zhijian, Gao, Lu, Xi, Mengyu, Zhou, Jinfeng, Li, Liping, Zhang, Hui, Feng, Qilin, Wang, Yingcong, Lu, Kang, Lu, Yumeng, Bu, Wenxuan, Wang, Houcai, Wu, Xiaosong, Zhu, Weiliang, Shi, Jumei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285565/
https://www.ncbi.nlm.nih.gov/pubmed/32517809
http://dx.doi.org/10.1186/s13046-020-01597-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285565/
https://www.ncbi.nlm.nih.gov/pubmed/32517809
http://dx.doi.org/10.1186/s13046-020-01597-9

Ejemplares similares